LR 20016
Alternative Names: LR-20016Latest Information Update: 03 Aug 2022
At a glance
- Originator LG Chem
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Atopic dermatitis
Most Recent Events
- 28 Jul 2022 LR 20016 is available for licensing as of 28 Jul 2022. https://innovation.lgchem.com/ResearchDevelopment/Partnership.do
- 21 Jul 2022 Preclinical trials in Atopic dermatitis in South Korea (unspecified route) Prior to July 2022